Concepedia

S. O' Brien

SO

4

Publications

110

Citations

4

H-Index

2001

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

S. O' Brien is an author at The University of Texas MD Anderson Cancer Center specializing in pharmacotherapy, oncology, and medicine.

Top concepts

MedicineOncologyPharmacotherapyPathologyHematologyImmunologyPharmacologyHealthImmunotherapyCancer Research

Publications per year

2001–2008

4

Publications

4

Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia

William G. Wierda, O apos, S. O' Brien et al. · 2001 · 50 citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +9

BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience

Abir Elfiky, Muhammad Wasif Saif, M. Beeram et al. · Journal of Clinical Oncology · 2008 · 39 citations

Pathology, Pharmacotherapy, Antimicrobial Chemotherapy +19

Lumiliximab in combination with FCR for the treatment of relapsed chronic lymphocytic leukemia (CLL): results from a phase I/II multicenter study

John C. Byrd, J. E. Castro, Ian W. Flinn et al. · Journal of Clinical Oncology · 2008 · 11 citations

Immunology, Pathology, Cll B Cells +17

Beta-2 microglobulin (B2M) is an independent prognostic factor for clinical outcomes in patients with CLL treated with frontline fludarabine, cyclophosphamide, and rituximab (FCR) regardless of age, creatinine clearance (CrCl)

Apostolia M. Tsimberidou, Constantine S. Tam, William G. Wierda et al. · Journal of Clinical Oncology · 2007 · 10 citations

Immunology, Pathology, Pharmacotherapy +16

Rows per page

1–4 of 4